造血干细胞移植后巨细胞病毒感染的细胞免疫治疗  

Cellular immunotherapy for cytomegalovirus infection after hematopoietic stem cell transplantation

作　　者：童娟[1] 孙自敏[1] 

机构地区：[1]安徽省立医院血液科,合肥230001

出　　处：《国际输血及血液学杂志》2015年第6期517-521,共5页International Journal of Blood Transfusion and Hematology

基　　金：安徽省高等学校省级科学研究项目资助（KJ20132123）

摘　　要：造血干细胞移植（HSCT）后由于患者免疫功能下降,巨细胞病毒（CMV）感染的发生率显著增高.抗CMV药物主要包括更昔洛韦及磷甲酸钠等,但抗CMV药物治疗容易导致病毒耐药及患者免疫功能进一步下降,致使HSCT后晚期的CMV感染比例增加.因此,细胞免疫治疗已成为HSCT后CMV感染预防与治疗的新方法,已在全球多个国家开展Ⅱ期及Ⅲ期临床试验,研究结果均证实细胞免疫治疗对于HSCT后CMV感染疗效良好,且发生移植物抗宿主病（GVHD）风险较低,笔者拟就HSCT后CMV感染的细胞免疫治疗进行综述.The incidence of cytomegalovirus （CMV） infection was significantly increased due to the impaired immune function of the patients after hematopoietic stem cell transplantation （HSCT）.Anti CMV drugs mainly include ganciclovir and foscarnet,which will decline the immune function of the patients and easily lead to a further virus resistance,and the late-onset CMV disease may actually increase.Therefore,cellular immunotherapy has become a new prevention and therapy of CMV,and the phase Ⅱ and phase Ⅲ clinical trials are being carried out in many countries.It is confirmed that cellular immunotherapy is effective on CMV infection and it is rarely caused the risk of graft versus host disease（GVHD）.This article reviews literatures on the cellular immunotherapy of CMV infection.

关 键 词：巨细胞病毒 免疫治疗 造血干细胞移植 

分 类 号：R457.7[医药卫生—治疗学]